Last updated: February 22, 2026
What is NDC 51407-0639?
NDC 51407-0639 corresponds to Procainamide Hydrochloride Injection, a drug used primarily for treating certain types of cardiac arrhythmias. It is supplied as a sterile solution intended for intravenous use.
Market Overview
Indications and Usage
Procainamide is primarily prescribed for ventricular and atrial arrhythmias, including:
- Sustained ventricular tachycardia
- Atrial fibrillation with Wolff-Parkinson-White syndrome
- Other narrow QRS complex ventricular rhythms
It involves inpatient administration typically under cardiology oversight.
Manufacturing and Supply Dynamics
Multiple manufacturers supply procainamide, including major generic companies and compounding pharmacies. The drug’s active pharmaceutical ingredient (API) is produced globally, with manufacturing concentrated in India, China, and the US.
FDA approvals are limited to sterile formulations produced under good manufacturing practices (GMP).
Market Size and Trends
The global antiarrhythmic drugs market was valued at approximately USD 1.2 billion in 2021. Procainamide ranks as a lower market share medication, replaced in many cases by amiodarone, lidocaine, and other agents.
Estimated annual US prescriptions for procainamide are around 4,000–6,000 units, reflecting declining utilization. The trend shows steady decrease over the past five years due to safety concerns and newer therapies.
Competitive Landscape
Main competitors include:
- Amiodarone
- Lidocaine
- Flecainide
These drugs often have preferred safety profiles and broader indications. Value chains involve hospital procurement and specialty pharmacy channels.
Price Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximately USD 25–USD 35 per 50 mL vial.
- Average selling price (ASP): Around USD 30–USD 40 per vial.
- Prices can vary based on supplier, location, and volume.
Future Price Trends
Factors influencing price changes:
- Supply chain disruptions: Raw material shortages could lead to temporary price increases.
- Regulatory shifts: New regulations on sterile manufacturing may impact costs.
- Market demand: Continued decline in use could drive prices downward, but low-volume niche markets may sustain current levels.
Price Projections (Next 5 Years)
| Year |
Expected Price Range (USD per vial) |
Key Factors |
| 2023 |
25–40 |
Stable demand with slight price pressure |
| 2024 |
24–38 |
Increased competition from generics |
| 2025 |
23–36 |
Consolidation in supply chain |
| 2026 |
22–35 |
Market stabilization, low demand persists |
| 2027 |
22–34 |
Continued decline; niche market exists |
Note: These figures assume no major regulatory or supply disruptions.
Pricing Strategies and Market Opportunities
- Generic suppliers can target hospital procurement channels with competitive pricing.
- Market entry can focus on niche markets where branded or compounded formulations are used.
- Price stability depends on maintaining quality standards and ensuring supply chain continuity.
Key Market Drivers and Risks
Drivers
- Increasing incidence of arrhythmia-related hospitalizations.
- Aging population with higher cardiovascular disease prevalence.
- Medical guidelines favoring intravenous antiarrhythmics for acute management.
Risks
- Decline in overall procainamide use due to safety concerns.
- Strict regulatory environment increasing manufacturing costs.
- Emergence of newer, safer antiarrhythmic drugs.
Regulatory Considerations
Procainamide is a long-established generic drug. FDA approval covers sterile injectable formulations. Any new claim or indication may require supplemental NDA filings.
Conclusions
Procainamide injection faces a declining market, with modest price stability driven by niche usage. Price projections are cautious, with potential slight decreases over the next five years, influenced by supply chain factors and shifting clinical preferences.
Key Takeaways
- The global market for procainamide is shrinking, with annual US prescriptions below 6,000 units.
- Current WAC prices are USD 25–USD 35 per vial, with slight downward pressure forecasted.
- Main competitors include amiodarone and lidocaine, which replace procainamide in many clinical settings.
- Market growth opportunities exist primarily in specialty hospitals and compounding segments.
- Regulatory and safety considerations will influence pricing and market presence.
Frequently Asked Questions
1. Why is the use of procainamide declining?
Clinical guidelines favor newer antiarrhythmics with better safety profiles, reducing reliance on procainamide.
2. Are there shortages of procainamide?
Supply chain issues, raw material costs, and manufacturing regulations can cause intermittent shortages, but availability remains stable.
3. What are the main competitors to procainamide?
Amiodarone, lidocaine, and other class I antiarrhythmics dominate the market.
4. How can market entrants succeed?
Focus on niche markets where compounding pharmacies or hospitals still prioritize procainamide, emphasizing quality and price competitiveness.
5. Are there ongoing regulatory changes impacting procainamide?
Current regulations are stable, but future changes in compounded drug rules or GMP standards could affect production costs.
References
- IQVIA. (2022). Global Antiarrhythmic Drugs Market Report.
- FDA. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
- CDC. (2021). Cardiovascular Disease Statistics.
- Statista. (2022). Market Revenue of Antiarrhythmic Drugs Worldwide.
- GoodRx. (2023). Procainamide Injection Pricing Data.
